The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC.sub.50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.

The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC.sub.50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.

The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Disclosed are alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester used in compositions and methods for inhibiting corrosion. The alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester are reaction products of an alkyl lactone and an amine, and an alkyl lactone and an alcohol, respectively.

Disclosed are alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester used in compositions and methods for inhibiting corrosion. The alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester are reaction products of an alkyl lactone and an amine, and an alkyl lactone and an alcohol, respectively.

Methods of controlling clay swelling and stabilizing subterranean geological formations containing swellable clays (e.g., montmorillonite, bentonite) are described. The methods involve treating the swellable clays with a composition containing an amidoamine-based gemini surfactant. The gemini surfactant has dual chains connected via an alkylene linker, whereby each chain contains a quaternary ammonium head group and an ethoxylated alkyl tail. As examined by linear swelling and free swelling tests, use of the gemini surfactant is effective in reducing swelling of the clays.

Methods of controlling clay swelling and stabilizing subterranean geological formations containing swellable clays (e.g., montmorillonite, bentonite) are described. The methods involve treating the swellable clays with a composition containing an amidoamine-based gemini surfactant. The gemini surfactant has dual chains connected via an alkylene linker, whereby each chain contains a quaternary ammonium head group and an ethoxylated alkyl tail. As examined by linear swelling and free swelling tests, use of the gemini surfactant is effective in reducing swelling of the clays.

The invention discloses a three-dimensional cage-like hyperbranched monomer and preparation method and application thereof. The three-dimensional cage-like hyperbranched monomer has the structural formula I:

in the formula: X is any one of —O, —S, —NH; y is any integer from 2 to 8; R is —H or —CH.sub.3. The beneficial effect of the technical scheme proposed in the present invention is: by introducing easily polymerizable olefin groups, the carboxyl group and amide group are combined in the three-dimensional cage-like hyperbranched monomer to make the water solubility good, and it can be copolymerized with many other monomers to obtain the three-dimensional cage-like hyperbranched polymer; when used as an additive for wellbore working fluids, due to the hyperbranched structure of the polymer, it has good salt and temperature resistance, and also has viscosity increasing, filtration loss, and flocculation properties; meanwhile, the synthesis method is simple and the cost is low.